Cystic Fibrosis #3: Management of Acute Pulmonary Exacerbations: Pseudomonas and Beyond

Module 3 addresses the management of infections in CF patients and the use of antibiotics in CF patients. It will review the PK and PD considerations to in these patients. This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.

Cystic Fibrosis #4: Adherence, Access, Education: Current Challenges and Overcoming Barriers in CF Medications

Module 4 discusses the importance of adherence in CF patients and will address the role of education to improve the treatment of CF patients. This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.

Desensitization to Antibiotic Allergies

This activity will use five clinical scenarios to explore treatment options for patients with antibiotic allergies. SIDP Members visit www.SIDP.org/MbrRate for member pricing.

Dueling Recommendations: When to Use Dual Therapy

This presentation will focus on the highlights and recent developments of combination therapy.

Emerging Practices in the Management of Community-Acquired Bacterial Pneumonia

This continuing education activity will explore the current prevalence and burden of CABP, discuss practice considerations in the use of rapid diagnostics, and examine studies and data surrounding the use of antibiotics currently available as well as emerging agents in the pipeline.

Enzyme Replacement Therapies

Three LSDs will be discussed (Gaucher, Anderson-Fabry and Pompe). For each disease, biomarkers, symptoms, complications and other therapeutic options besides ERTs will be addressed. Available for free to NASP members. Visit www.ProCE.com/CSPE for details.

Evaluating Practices in the Treatment of HABP/VABP

This activity will discuss the prevention and treatment of HABP/VABP for clinical and infectious diseases pharmacists. Special attention will be given to available and emerging treatment options, along with pertinent patient considerations and monitoring strategies.

Examining Sterile Compounding for Health-Systems: A Look Ahead to 2020

A discussion surrounding the finalized update to USP <797> and current understanding of USP <800> will ensure learners are up to date on necessary compliance elements for their health-systems.

Examining Strategies to Manage Antimicrobial Resistance Mechanisms

This activity will discuss mechanisms of resistance, management strategies for highlighted community and hospital-acquired infectious diseases with the most resistance-related concerns, and substitute therapeutic options when guideline or protocol-directed therapies are found to be ineffective.

Expert Answers: Sterile Compounding in Health Systems

Faculty will shed light on difficult concepts and common concerns related to the implementation of new sterile compounding regulations, while providing attendees with immediate feedback and reinforcement of key points.